Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Immix Biopharma, Inc. IMMX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$13.00
+32%

Immix Biopharma, Inc. (IMMX) is a Biotechnology company in the Healthcare sector, currently trading at $9.85. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is IMMX = $13 (+32% upside).

Valuation: IMMX trades at a trailing Price-to-Earnings (P/E) of -12 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.17.

Net income is $29M (loss), growing at -54.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $94M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 10.01 (strong liquidity). Debt-to-assets is 1%. Total assets: $105M.

Analyst outlook: 4 / 4 analysts rate IMMX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 65/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$13.00
▲ 31.98% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Immix Biopharma, Inc., the average price target is $13.00, with a high forecast of $14.00, and a low forecast of $12.00.
Highest Price Target
$14.00
Average Price Target
$13.00
Lowest Price Target
$12.00

IMMX SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 65/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IMMX

✓
VALUE Pass
65/100
IMMX trades at a trailing Price-to-Earnings (P/E) of -12 (S&P 500 average ~25). Forward PEG 2.17 — overvalued. Trailing PEG 0.85. Analyst consensus target is $13, implying +32% from the current price $10. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
IMMX: +0%/yr revenue is, -54.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet IMMX: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 10.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
IMMX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate IMMX as buy (100%). Analyst consensus target is $13 (+32% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.34-11.61
Volume508.8K
Avg Volume (30D)830.03K
Market Cap$521.7M
Beta (1Y)0.21
Share Statistics
EPS (TTM)-0.89
Shares Outstanding$32.97M
IPO Date2021-12-16
Employees18
CEOGraham Ross
Financial Highlights & Ratios
Gross Profit$-364.5K
EBITDA$-26.85M
Net Income$-29.44M
Operating Income$-27.21M
Total Cash$100.41M
Total Debt$1.07M
Net Debt$-92.86M
Total Assets$104.84M
Price / Earnings (P/E)-11.1
Analyst Forecast
1Y Price Target$13.00
Target High$14.00
Target Low$12.00
Upside+32.0%
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS45258H1068

Price Chart

Track all markets on TradingView
IMMX
Immix Biopharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.34 52WK RANGE 11.61

People Also View

FRLN
FRLN
Freeline Therapeutics Holdings plc
$6.49
+0.15%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
-8.57%
 CNSP
CNSP
CNS Pharmaceuticals, Inc.
$2.64
+5.18%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
 ENVB
ENVB
Enveric Biosciences, Inc.
$1.95
-1.02%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message